Related Experiment Video
Updated: Feb 4, 2026

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Identification of TAF1, HNF4A, and CALM2 as potential therapeutic target genes for liver fibrosis
Dong Ji1, Guo-Feng Chen1, Jin-Cheng Wang2
1Liver Cirrhosis Treatment and Research Center II, 302 Military Hospital of China, Beijing, China.
Abstract:
The molecular mechanism of liver fibrosis caused by hepatitis C virus (HCV) is not clear. The aim of this study is to understand the molecular mechanism of liver fibrosis induced by HCV and to identify potential therapeutic targets for hepatic fibrosis. We analyzed gene expression patterns between high liver fibrosis and low liver fibrosis samples, and identified genes related to liver fibrosis. We identified TAF1, HNF4A, and CALM2 were related to the development of liver fibrosis. HNF4A is important for hepatic fibrogenesis, and upregulation of HNF4A is an ideal choice for treating liver fibrosis. The gene expression of CALM2 is significantly lower in liver fibrosis samples than nonfibrotic samples. TAF1 may serve as a biomarker for liver fibrosis. The results were further validated by an independent data set GSE84044. In summary, our study described changes in the gene expression during the occurrence and development of liver fibrosis. The TAF1, HNF4A, and CALM2 may serve as novel targets for the treatment of liver fibrosis.
Insights
Hepatitis C virus-induced liver fibrosis mechanisms were explored. TAF1, HNF4A, and CALM2 genes were identified as key players, offering potential therapeutic targets for hepatic fibrosis treatment.
Area of Science:
- Hepatology
- Molecular Biology
- Virology
Background:
- The molecular mechanisms underlying liver fibrosis development in Hepatitis C Virus (HCV) infection remain incompletely understood.
- Identifying specific molecular pathways and therapeutic targets is crucial for managing hepatic fibrosis progression.
Purpose of the Study:
- To elucidate the molecular mechanisms of liver fibrosis induced by HCV.
- To identify novel therapeutic targets for hepatic fibrosis.
Main Methods:
- Comparative analysis of gene expression patterns in high versus low liver fibrosis samples.
- Validation of identified gene markers using an independent dataset (GSE84044).
Main Results:
- TAF1, HNF4A, and CALM2 were identified as genes associated with liver fibrosis development.
- HNF4A was highlighted as crucial for hepatic fibrogenesis, suggesting its upregulation as a therapeutic strategy.
- CALM2 expression was significantly reduced in fibrotic liver samples.
- TAF1 demonstrated potential as a reliable biomarker for liver fibrosis.
Conclusions:
- The study delineates key gene expression alterations during the occurrence and progression of liver fibrosis.
- TAF1, HNF4A, and CALM2 represent promising novel molecular targets for the treatment of liver fibrosis.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cell Specific Gene Expression
Therapeutic Index
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Cystic Fibrosis: Management
Sinus disease and chronic...
Standard Electrode Potentials

